Urgent

Membranoproliferative GN and C3 glomerulopathy

MPGN/C3G · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A pattern of glomerular injury with mesangial/capillary wall proliferation, now classified by immunofluorescence into immune-complex-mediated MPGN and complement-mediated C3 glomerulopathy. Work-up targets infection, autoimmunity, paraproteins and alternative complement pathway dysregulation.

Red flags

  • Rapidly progressive renal failure (crescents on biopsy)
  • Nephrotic syndrome with thrombosis
  • Underlying monoclonal gammopathy
  • Cryoglobulinaemia with systemic vasculitis
  • Recurrent disease in a transplant

Assessment

Differential diagnosis

  • Immune-complex MPGN (hepatitis C/B, cryoglobulinaemia, autoimmune)
  • C3 glomerulopathy (C3GN, dense deposit disease)
  • Monoclonal gammopathy-associated MPGN
  • Post-infectious/infection-related GN
  • Lupus nephritis
  • Thrombotic microangiopathy (overlapping pattern)

Investigations

  • Complement C3 and C4 (low C3 with normal C4 suggests alternative pathway/C3G)
  • Hepatitis B/C serology, cryoglobulins, ANA/dsDNA
  • Serum/urine electrophoresis and free light chains (paraprotein)
  • Complement functional assays (C3 nephritic factor, factor H/I) in C3G
  • Urinalysis/ACR/PCR and renal function
  • Renal biopsy with immunofluorescence and electron microscopy (defines subtype)

Management

  • Recognise the nephritic/nephrotic mixed picture and arrange renal biopsy to define the MPGN pattern and immunofluorescence subtype
  • Check complement: low C3 with normal C4 points to alternative-pathway/C3 glomerulopathy
  • Screen exhaustively for secondary causes: hepatitis B/C, cryoglobulins, autoimmune disease and monoclonal gammopathy
  • Treat the underlying cause when identified (e.g. antiviral therapy for hepatitis C, treat the clone in MGRS-associated disease)
  • Provide supportive nephroprotection: RAAS blockade, BP control and proteinuria reduction
  • For idiopathic immune-complex MPGN with significant disease, consider immunosuppression (steroids +/- other agents) per severity
  • For C3 glomerulopathy, pursue complement work-up (nephritic factors, genetic/factor assays) via specialist services
  • Consider complement-directed therapy (e.g. eculizumab) in selected rapidly progressive C3G at specialist centres
  • Manage nephrotic complications (oedema, thrombosis risk, hyperlipidaemia)
  • Monitor renal function, proteinuria and complement response
  • Plan for transplantation awareness — C3G and MPGN frequently recur in grafts
  • Provide long-term nephrology follow-up and genetic counselling in complement-mediated disease

Drugs & doses

Ramipril 2.5-10 mg PO daily OR losartan 50-100 mg PO daily (nephroprotection)
Prednisolone 1 mg/kg/day PO (selected idiopathic immune-complex MPGN), tapered
Mycophenolate mofetil 500-1000 mg PO twice daily (steroid-sparing in selected cases)
Direct-acting antivirals for hepatitis C-associated cryoglobulinaemic MPGN (per hepatology)
Eculizumab (specialist, dosed per protocol) for selected rapidly progressive C3 glomerulopathy
Atorvastatin 20-80 mg PO daily (nephrotic dyslipidaemia)

Disposition

Nephrology management with renal biopsy; specialist complement/glomerular service for C3 glomerulopathy. Haematology for paraprotein-associated disease. Transplant counselling on recurrence.

Complications & pitfalls

  • Progression to end-stage kidney disease
  • Nephrotic complications (thrombosis, infection, hyperlipidaemia)
  • Disease recurrence after transplantation
  • Complement dysregulation-driven relapse
  • Treatment-related immunosuppression toxicity

Exam pearls

  • Immunofluorescence reclassifies MPGN into immune-complex vs C3 glomerulopathy — this drives work-up
  • Low C3 with normal C4 flags the alternative complement pathway (C3G)
  • Always exclude hepatitis C, cryoglobulins and a monoclonal protein
  • C3 glomerulopathy and MPGN commonly recur after transplantation
  • Treat the cause (virus, clone) where one is found rather than immunosuppressing blindly

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.